Insulet Corporation PODD
146.51 USD -9.61 (-6.16%)
At closeNov 6, 2026, 6:16 PM EST
146.61 +0.10 +0.07%
After hours · Nov 6, 6:16 PM ET
143.28 Day range 155.60
130.47 52-week range 346.36
- YTD
- -48.46%
- 1 year
- -54.70%
News
benzinga.com Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $165 Barclays analyst Christopher Pasquale maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $150 to $165.
benzinga.com UBS Maintains Neutral on Insulet, Raises Price Target to $171 UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $150 to $171.
benzinga.com JP Morgan Maintains Neutral on Insulet, Raises Price Target to $170 JP Morgan analyst Robbie Marcus maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $152 to $170.- benzinga.com Citigroup Maintains Neutral on Insulet, Raises Price Target to $170 Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $150 to $170.
- benzinga.com Leerink Partners Maintains Market Perform on Insulet, Raises Price Target to $167 Leerink Partners analyst Mike Kratky maintains Insulet (NASDAQ:PODD) with a Market Perform and raises the price target from $143 to $167.
- benzinga.com RBC Capital Maintains Outperform on Insulet, Raises Price Target to $180 RBC Capital analyst Kendall Au maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $160 to $180.
benzinga.com Bernstein Maintains Outperform on Insulet, Raises Price Target to $200 Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $175 to $200.
benzinga.com Wells Fargo Maintains Equal-Weight on Insulet, Raises Price Target to $172 Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $144 to $172.
benzinga.com Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share Insulet stock jumps on strong Q3 results, beating estimates with $842M in revenue, raising its 2026 outlook, and launching a $1B buyback.
marketbeat.com What Insulet (PODD) Said on Its Q3 Earnings Call Insulet NASDAQ: PODD reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company's plans and U.S.…
seekingalpha.com Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript
zacks.com Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
zacks.com Insulet (PODD) Q3 Earnings and Revenues Surpass Estimates Insulet (PODD) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.24 per share a year ago.
benzinga.com Insulet Q3 2026 Earnings Call Transcript Insulet (NASDAQ:PODD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.46 Est; Raises FY2026 Sales Guidance from $3.250B-$3.304B to $3.277B-$3.304B vs $3.289B Est Insulet (NASDAQ:PODD) FY2026 expected to be more than $6.46 vs $6.46 Est. raises FY2026 sales outlook from $3.250 billion-$3.304 billion to $3.277 billion-$3.304 billion vs $3.289 billion estimate.- benzinga.com Insulet Q3 Adj. EPS $1.99 Beats $1.59 Estimate, Sales $842.000M Beat $832.685M Estimate Insulet (NASDAQ:PODD) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $1.59 by 25.16 percent. This is a 60.48 percent increase over earnings of $1.24 per…
businesswire.com Insulet Reports Third Quarter 2026 Results ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced…
businesswire.com Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will…
defenseworld.net Insulet Corporation $PODD Stock: International Assets Investment Management LLC Boosts Stake International Assets Investment Management LLC grew its position in Insulet Corporation (NASDAQ: PODD) by 61,543.8% during the undefined quarter, according to the company in its most recent…- benzinga.com Jefferies Maintains Buy on Insulet, Lowers Price Target to $190 Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $275 to $190.
benzinga.com Insulet Reports Q2 2026 Results: Full Earnings Call Transcript Insulet (NASDAQ:PODD) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…- finance.yahoo.com Cerebras Systems Inc. (CBRS) Cerebras faces two near-term tests: a November 9 share lockup expiration and third-quarter results due November 12. Recent coverage highlights strong revenue growth, Oracle-related demand, and large…
finance.yahoo.com What Is Behind The Move In DexCom Stock? DexCom (DXCM) stock fell 6.0% on Friday, November 6, 2026, while the S&P 500 gained 0.3%. The company released no ...
theglobeandmail.com Stifel Nicolaus Reaffirms Their Buy Rating on Insulet (PODD) In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Insulet, with a price target of $180.00. Block covers the Healthcare sector, focusing on stocks such as ...
theglobeandmail.com Analysts’ Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (VRDN), Insulet (PODD) and BeOne Medicines (ONC) Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics , Insulet and BeOne Medicines . Viridian Therapeutics (VRDN) ...